Drugs / HER2 DC1 Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03630809 | Jan 2019 → Apr 2022 | HER2 positive breast carcinoma, female breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2 DC1 Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03630809 ↗ |
| Modality | Vaccine | “This study will use a Dendritic Cell Type 1 (DC1) vaccine which is a HER2-sensitized dendritic cell (DC) study vaccine.” NCT03630809 ↗ |
| Route | Other | “Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site” NCT03630809 ↗ |